Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 62, Issue SUPPL.160, 2008, Pages 5-9

  Doran, A K ^a   Ivy, D D ^a   Barst, R J ^b   Hill, N ^c   Murali, S ^d   Benza, R L ^e  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROSTACYCLIN; UNIPROST; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN;

BACTEREMIA; CAREGIVER; CATHETER CARE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL PRACTICE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION RISK; MORBIDITY; MORTALITY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; UNITED STATES; ARTICLE; CROSS INFECTION; EQUIPMENT; INDWELLING CATHETER; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY;

ANTIHYPERTENSIVE AGENTS; BACTEREMIA; CATHETERS, INDWELLING; CROSS INFECTION; EQUIPMENT CONTAMINATION; HOME INFUSION THERAPY; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; PROSTAGLANDINS;

EID: 47349126435     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01811.x     Document Type: Review

References (20)

1. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002 106 : 1477 82.
2. Gomberg-Maitland M, Tapson VF, Benza R. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005 172 : 1586 9.
3. Sitbon O, Humbert M, Nunes H. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 40 : 780 8.
4. Tapson VF, Gomberg-Maitland M, McLaughlin VV. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12 week trial. Chest 2006 129 : 683 8.
5. Roberts TG, Chabnar BA. Beyond fast track for drug approvals. N Engl Med 2004 351 : 683 8.
6. Oudiz RJ, Widlitz A, Backman XJ. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004 126 : 90 4.
7. Centers for Disease Control and Prevention. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States 2003-2006. Morb Mortal Wkly Rep 2007 56 : 170 2.
8. Kallen A, Lederman E, Balaji A. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008 29 : 342 9.
9. Norgaard M, Larsson H, Pedersen G. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br J Haematol 2006 132 : 25 31.
10. Salzman MB, Rubin LG. Relevance of the catheter hub as a portal for microorganisms causing catheter-related bloodstream infections. Nutrition 1997 4 (Suppl. 15S 7S.
11. Akagi S, Matsubara H, Ogawa A. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J 2007 71 : 559 64.
12. Rupp ME, Scholtz LA, Jourdan DR. Outbreak of bloodstream infection temporally associated with the use of an intravascular needless valve. CID 2007 44 : 1408 14.
13. Maragakis LL, Bradley KL, Song X. Increased catheter-related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol 2006 27 : 67 70.
14. O'Grady NP, Alexander M, Dellinger EP. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, u.s. Pediatrics 2002 110 : e51.
15. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002 34 : 1232 42.
16. Hoffmann KK. Transparent polyurethane film as an intravenous catheter dressing. A metaanalysis of infection risks. JAMA 1992 267 : 2072 6.
17. Package Insert. Flolan (Epoprostenol). Research Triangle Park, NC : GlaxoSmithKline, 2002.
18. Phares KR, Weiser WE, Miller SR. Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. Am J Health Syst Pharm 2003 60 : 916 22.
19. Package Insert. Remodulin (Treprostinil). Research Triangle Park, NC : United Therapeutics Corp., 2008.
20. 30-day Multipuncture Study with Remodulin (1 and 10mg/mL). Technical Test Protocol (TTP-LRR-Mo292). Research Triangle Park, NC : United Therapeutics Corporation, 2006.